Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.70 |
| ▸ | MGAM | O43451 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | SI | P14410 | 1/20 | 0.55 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6421942 | 0.97 | TSHR (0.67) | TSHRMGAMGAASIMGAM2 | |
| SCHEMBL3628963 | 0.97 | TSHR (0.67) | TSHRMGAMGAASIMGAM2 | |
| SCHEMBL16902770 | 0.97 | TSHR (0.67) | TSHRMGAMGAASIMGAM2 | |
| SCHEMBL7941508 | 0.97 | TSHR (0.67) | TSHRMGAMGAASIMGAM2 | |
| SCHEMBL3626724 | 0.97 | TSHR (0.67) | TSHRMGAMGAASIMGAM2 | |
| SCHEMBL6821595 | 0.97 | TSHR (0.67) | TSHRMGAMGAASIMGAM2 | |
| SCHEMBL437127 | 0.95 | TSHR (0.79) | TSHRMGAMGAASIMGAM2 | |
| SCHEMBL11955444 | 0.93 | TSHR (0.61) | TSHRMGAMGAASIMGAM2 | |
| SCHEMBL22122660 | 0.91 | TSHR (0.58) | TSHRMGAMGAASIMGAM2 | |
| SCHEMBL10631996 | 0.89 | TSHR (0.56) | TSHRLMNAALDH1A1CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118026995-A | Dihydrotriazole aromatization precursor and application thereof in deacylating and arylating reaction of ketone | 国科大杭州高等研究院 | 2024-05-14 | — | — | CN | claimed |
| EP-4159727-B1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC INC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12415796-B2 | Inhibitors of (αv)(β6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2025-09-16 | — | — | US | disclosed |
| US-20250223289-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | SCHRODINGER, INC. | 2025-07-10 | — | — | US | disclosed |
| WO-2025129104-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SIONNA THERAPEUTICS INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| US-12145935-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| US-20240327378-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2024-10-03 | — | — | US | disclosed |
| EP-4056670-B1 | METHOD FOR FRACTIONATING A SHEA EXTRACT | BIOSYNTHIS SARL (FR) | 2024-08-21 | — | — | EP | disclosed |
| US-20240158719-A1 | METHOD FOR FRACTIONATING A SHEA EXTRACT | BIOSYNTHIS (FR) | 2024-05-16 | — | — | US | disclosed |
| CN-118026995-A | Dihydrotriazole aromatization precursor and application thereof in deacylating and arylating reaction of ketone | 国科大杭州高等研究院 | 2024-05-14 | — | — | CN | disclosed |
| EP-1040098-A1 | INTEGRIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (a New Jersey corp.) (US) | 2000-10-04 | — | — | EP | disclosed |
| WO-2000034254-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2000-06-15 | — | — | WO | disclosed |
| US-6048861-A | OSTEOPOROSIS; BONE DISORDERS; CARDIOVASCULAR DISORDERS; ANTIINFLAMMATROY AGENTS; WOUND HEALING AGENTS | MERCK & CO., INC. (US) | 2000-04-11 | — | — | US | disclosed |
| WO-1999031061-A1 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| US-5639780-A | NON-STEROIDAL ANTIINFLAMMATORY AGENTS | MERCK FROSST CANADA, INC. (CA) | 1997-06-17 | — | — | US | disclosed |
| WO-1996037467-A1 | N-BENZYLINDOL-3-YL BUTANOIC ACID DERIVATIVES AS CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1996-11-28 | — | — | WO | disclosed |
| WO-1995035161-A1 | A MEMBRANE REACTOR | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1995-12-28 | — | — | WO | disclosed |
| US-4983767-A | Vanadium compound as catalyst | RHONE-POULENC CHIMIE (FR) | 1991-01-08 | — | — | US | disclosed |
| US-4259527-A | OXIDATION OF SECONDARY ALCOHOLS TO KETONES WITH HYDROGEN PEROXIDE | ALLIED CHEMICAL CORPORATION (US) | 1981-03-31 | — | — | US | disclosed |
| US-4171313-A | OF ALICYCLIC KETONES TO LACTONES, W-HYDROXY ACIDS AND ESTERS USING HYDROGEN PEROXIDE AS AN OXIDIZING AGENT | ALLIED CHEMICAL CORPORATION (US) | 1979-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327378-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | TSHR 2084/4885MGAM 892/4885GAA 388/4885 |
| US-20250223289-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | TSHR 2021/4885MGAM 961/4885GAA 346/4885 |
| US-12415796-B2 | Inhibitors of (αv)(β6) integrin | ITGB6, ITGA6, ITGAV | TSHR 2173/4885MGAM 788/4885GAA 451/4885 |
| US-12145935-B2 | Inhibitors of (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | TSHR 1938/4885MGAM 947/4885GAA 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.